Dynavax Technologies Corporation (DVAX)
Automate Your Wheel Strategy on DVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including DVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DVAX
- Rev/Share 2.3594
- Book/Share 4.2519
- PB 2.3084
- Debt/Equity 0.5387
- CurrentRatio 11.933
- ROIC -0.0112
- MktCap 1178595015.0
- FreeCF/Share 0.4326
- PFCF 21.8173
- PE -20.4034
- Debt/Assets 0.3024
- DivYield 0
- ROE -0.098
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DVAX | Goldman | Neutral | Sell | $15 | $12 | Feb. 11, 2025 |
News
Deep Track Capital Comments on ISS Recommendation
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Institutional Shareholder Services Inc. (“ISS”) regarding the election of directors to the Company's Board of Director.
Read More
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
Published: May 23, 2025 by: PRNewsWire
Sentiment: Neutral
ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS"), has recommended that Dynavax stockholders vote "FOR" all …
Read More
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balanced capital allocation program.
Read More
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 12, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed an investor presentation with the Securities and Exchange Commission ("SEC") in connection with its 2025 Annual Meeting of Stockholders to be held on June 11, 2025.
Read More
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being …
Read More
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.07 per share a year ago.
Read More
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatitis B virus Findings released during Hepatitis Awareness Month underscore the importance of public education to address misunderstandings about hepatitis B and raise awareness of the Centers for Disease Control and Prevention (CDC) universal recommendation that eligible adults over 19 receive the hepatitis B vaccine Results will be discussed with a panel of hepatitis B experts during the May 27th LinkedIn Live event EMERYVILLE, Calif. …
Read More
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today mailed a letter to its stockholders in connection with its 2025 Annual Meeting of Stockholders ("Annual Meeting") urging stockholders to vote the GOLD proxy card "FOR" all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun.
Read More
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Read More
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m.
Read More
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value.
Read More
About Dynavax Technologies Corporation (DVAX)
- IPO Date 2004-02-19
- Website https://www.dynavax.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Ryan Spencer
- Employees 405